Related Experiment Videos
Drug-induced liver disease 2004
Susan K Lazerow1, Maaza S Abdi, James H Lewis
1Division of Gastroenterology, Section of Hepatology, Georgetown University Medical Center, Washington, DC 20007, USA.
Current Opinion in Gastroenterology
|April 9, 2005
Summary
Acetaminophen (APAP) remains the primary cause of drug-induced acute liver failure and liver transplants. Further efforts are needed to reduce severe liver injury from this common medication.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Drug-induced liver disease (DILD) is a significant clinical concern.
- Understanding the epidemiology and clinical presentations of DILD is crucial for patient management.
Purpose of the Study:
- To review clinical, pathological, and epidemiological data on drug-induced liver disease in 2004.
- To identify emerging trends and key hepatotoxins reported during the year.
Main Methods:
- Systematic review of salient reviews, studies, and case reports from 2004.
- Analysis of clinical, pathological, and epidemiological descriptions of DILD.
Main Results:
- Acetaminophen (APAP) identified as the leading cause of drug-induced acute liver failure (nearly 50% of cases) and liver transplantation.
- New reports of previously recognized hepatotoxins, including herbal products, antiretrovirals, and tuberculosis agents.
- Statins demonstrated safety in patients with pre-existing liver disease.
Conclusions:
- Increased incidence of APAP-related acute liver failure in the US necessitates further risk assessment.
- Continued efforts are required to minimize severe liver injury from APAP.
- Ongoing monitoring of hepatotoxins is essential for public health.